1. Complementary and alternative medicine application in cancer patients in Iran

   • Nazi Nejat
   • Amir Rahbarian
   • Fatemeh Rafiei

   Original Article – Clinical Oncology 28 August 2022 Pages: 2271 - 2277

   

2. Immunohistochemical analysis of a panel of cancer stem cell markers and potential therapeutic markers in pancreatic ductal adenocarcinoma

   • S. M. Adnan Ali
   • Yumna Adnan
   • Hasnain Ahmed Farooqui

   Original Article – Clinical Oncology 06 September 2022 Pages: 2279 - 2292

   

3. Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma

   • Yunteng Wu
   • Dongliang Wei
   • Wei Guo

   Original Article – Clinical Oncology 11 September 2022 Pages: 2293 - 2300

   

4. Diagnostic role of plasma ORM2 in differentiating prostate cancer from benign prostatic hyperplasia

   • Yuqiu Ge
   • Bin Xu
   • Gaoxiang Ma

   Original Article – Clinical Oncology 05 October 2022 Pages: 2301 - 2310

   

5. Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era

   • Yi Chen
   • Luting Luo
   • Jianda Hu

   Original Article – Clinical Oncology 11 October 2022 Pages: 2311 - 2318

   

6. Heterozygous germline FLCN mutation in Birt–Hogg–Dubé syndrome with bilateral renal hybrid oncocytic/chromophobe tumor and unilateral renal chromophobe cell carcinoma: a case report

   • Jun Li
   • Fan Liu
   • Jie Wan

   Original Article – Clinical Oncology 18 October 2022 Pages: 2319 - 2325

   

7. Concurrent chemoradiotherapy combined with nimotuzumab in stage III–IVa nasopharyngeal carcinoma: a retrospective analysis

   • Zhuochen Cai
   • Dongni Chen
   • Xing Lv

   Original Article – Clinical Oncology 27 October 2022 Pages: 2327 - 2344

   

8. Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis

   • Timothy J. Brown
   • Ronac Mamtani
   • Yu-Xiao Yang

   Original Research 02 March 2023 Pages: 2345 - 2354

   

9. Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance

   • Jung Sun Kim
   • Soyeon Kim
   • Dong-Wan Kim

   OriginalPaper 17 August 2022 Pages: 2355 - 2365

   

10. Lymph node distribution in patients with remnant gastric cancer

    • Alexandre Augusto Ferreira Bafutto
    • Osvaldo Antonio Prado Castro
    • Paulo Kassab

    Research 21 June 2022 Pages: 2367 - 2374

    

11. Safety of sequential immune checkpoint inhibitors after prior immune therapy

    • Muhammad Awidi
    • Brendan Connell
    • Krishna S. Gunturu

    Research Open access 21 June 2022 Pages: 2375 - 2382

12. Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study

    • Lan Zhang
    • Xingnong Ye
    • Jian Huang

    Research 22 June 2022 Pages: 2383 - 2392

    

13. Metabolic pathway-based molecular subtyping of colon cancer reveals clinical immunotherapy potential and prognosis

    • Zhujiang Dai
    • Xiang Peng
    • Jinglue Song

    Research 22 June 2022 Pages: 2393 - 2416

    

14. Comprehensive immunohistochemical analysis of N6-methyladenosine (m6A) writers, erasers, and readers in endometrial cancer

    • Damian J. Ralser
    • Mateja Condic
    • Thore Thiesler

    Research Open access 22 June 2022 Pages: 2417 - 2424

    

15. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma

    • Shin Ishihara
    • Takeshi Iwasaki
    • Yoshinao Oda

    Research 23 June 2022 Pages: 2425 - 2436

    

16. Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model

    • Mojgan Ghaedi
    • Forough Golsaz-Shirazi
    • Fazel Shokri

    Research 23 June 2022 Pages: 2437 - 2450

    

17. Whole-exome sequencing of Indian prostate cancer reveals a novel therapeutic target: POLQ

    • Febina Ravindran
    • Anika Jain
    • Bibha Choudhary

    Research 23 June 2022 Pages: 2451 - 2462

    

18. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers

    • Klara Dorman
    • Miriam Gerckens
    • Stefan Holdenrieder

    Research Open access 23 June 2022 Pages: 2463 - 2474

    

19. Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study

    • Tae Hata
    • Chikara Sakaguchi
    • Yukio Nagasaka

    Research 23 June 2022 Pages: 2475 - 2482

    

20. The prognostic role of PSMD14 in head and neck squamous cell carcinoma

    • Julia Schnoell
    • Alexandra Scheiflinger
    • Bernhard J. Jank

    Research Open access 25 June 2022 Pages: 2483 - 2490

    

21. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study

    • Jinbin Chen
    • Peiyao Xiong
    • Li Xu

    Research 25 June 2022 Pages: 2491 - 2500

    

22. Expression pattern and prognostic potential of histamine receptors in epithelial ovarian cancer

    • Fabian B. T. Kraus
    • Nicole E. Topalov
    • B. Czogalla

    Research Open access 25 June 2022 Pages: 2501 - 2511

    

23. Combination therapy of doxorubicin and Sildenafil inhibits the growth of pediatric rhabdomyosarcoma

    • Cristian Urla
    • Matias Julian Stagno
    • Evi Schmid

    Research Open access 28 June 2022 Pages: 2513 - 2522

    

24. Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma

    • Sofya Marchenko
    • Iris Piwonski
    • Eliane Tabea Taube

    Research Open access 28 June 2022 Pages: 2523 - 2536

    

25. Implications for pelvic lymph node irradiation in definitive chemoradiotherapy of node negative muscle invasive bladder cancer based on predictive factors of clinicopathologic discrepancy

    • Arefeh Saeedian
    • Afsaneh Maddah Safaei
    • Ebrahim Esmati

    Research 28 June 2022 Pages: 2537 - 2542

26. Role of vascular endothelial growth factor in radiotherapy resistance to esophageal squamous cell carcinoma

    • Xin Li
    • Xinyu Su
    • Zhengyun Zou

    Research 29 June 2022 Pages: 2543 - 2550

    

27. Chronological development of in-patient oncology in times of COVID-19: a retrospective analysis of hospitalized oncology and COVID-19 patients of a German University Hospital

    • Sebastian Griewing
    • Uwe Wagner
    • Matthias Kalder

    Research Open access 30 June 2022 Pages: 2551 - 2558

    

28. TKIs beyond immunotherapy predict improved survival in advanced HCC

    • Samantha Armstrong
    • Tina Roy
    • Aiwu Ruth He

    Research 30 June 2022 Pages: 2559 - 2574

    

29. Combined diagnosis of multiparametric MRI-based deep learning models facilitates differentiating triple-negative breast cancer from fibroadenoma magnetic resonance BI-RADS 4 lesions

    • Hao-lin Yin
    • Yu Jiang
    • Guang-wu Lin

    Research 30 June 2022 Pages: 2575 - 2584

    

30. A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif^® in healthy Chinese subjects

    • Guangwen Liu
    • Jinling Xue
    • Haimiao Yang

    Research 30 June 2022 Pages: 2585 - 2593

    

31. Targeting the (pro)renin receptor in cancers: from signaling to pathophysiological effects

    • Xin Ouyang
    • Chuanming Xu

    Review 25 September 2022 Pages: 2595 - 2605

    

32. Bioenergy therapies as a complementary treatment: a systematic review to evaluate the efficacy of bioenergy therapies in relieving treatment toxicities in patients with cancer

    • M. Hauptmann
    • S. Kutschan
    • J. Dörfler

    Review Open access 27 September 2022 Pages: 2607 - 2619

    

33. BDNF and its signaling in cancer

    • Mohammad Malekan
    • Sasan Salehi Nezamabadi
    • Nima Rezaei

    Review 29 September 2022 Pages: 2621 - 2636

    

34. Ten years of AMNOG from an oncological perspective: new horizons and continuing expansion

    • Arne Bartol
    • Katrin Dressler
    • Marco Petschulies

    Review 01 October 2022 Pages: 2637 - 2645

    

35. Heterogeneous molecular behavior in liver tumors (HCC and CCA) of two patients with acute intermittent porphyria

    • Thomas Haverkamp
    • Olivia Bronisch
    • Petro E. Petrides

    Review 16 October 2022 Pages: 2647 - 2655

    

36. Cancer-associated inflammation: pathophysiology and clinical significance

    • Piotr Pęczek
    • Monika Gajda
    • Anna M. Badowska-Kozakiewicz

    Review Open access 19 October 2022 Pages: 2657 - 2672

    

37. The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis

    • Aleksander Ślusarczyk
    • Piotr Zapała
    • Piotr Radziszewski

    Review Open access 21 November 2022 Pages: 2673 - 2691

    

38. Progress in the treatment of urethral adenocarcinoma

    • Jiamin Guo
    • Xiuping Liang
    • Ji Ma

    Review 21 November 2022 Pages: 2693 - 2698

    

39. The negative impact of opioids on cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

    • Mingguang Ju
    • Ziming Gao
    • Kai Li

    Review 20 December 2022 Pages: 2699 - 2708

    

40. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?

    • Konstantinos Drougkas
    • Konstantinos Karampinos
    • Elias Kotteas

    Review Open access 24 December 2022 Pages: 2709 - 2734